Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
NEW YORK, April 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011
http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html
Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011
Summary
GlobalData, the industry analysis specialist, has released its new report, "Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011". The report is an essential source of information and analysis on the global gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global gastric cancer therapeutics market. It analyses the treatment usage patterns in the global gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global gastric cancer sector. It quantifies the unmet need in the global gastric cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The Scope of the report includes:
- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global gastric cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.
- Clinical trials mapping of trials for gastric cancer in different regions.
- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the global Gastric Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key market players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka and Merck KGaA.
- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the global gastric cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the global gastric cancer therapeutics market till 2020.
- Quantifying patient population in the global gastric cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the global gastric cancer therapeutics market from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the global gastric cancer therapeutics market landscape? Identify, understand and capitalize
1 Table of contents
1 Table of contents 3
1.1 List of Tables 7
1.2 List of Figures 10
2 Introduction 14
2.1 Disease Overview 14
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 14
2.2 Epidemiology 16
2.3 Etiology 16
2.4 Symptoms 17
2.4.1 Initial Symptoms 17
2.4.2 Symptoms Observed in Later Stages 17
2.5 Diagnosis 18
2.5.1 Fecal Occult Blood Test (FOBT) 18
2.5.2 X-ray of Upper Gastrointestinal Tract (GI Series) 19
2.5.3 Endoscopy (Gastroscopy) 19
2.5.4 Computed Tomography (CT) 20
2.5.5 Biopsy 20
2.6 Pathology 20
2.6.1 Grading 21
2.7 Prognosis 22
2.8 Treatment 22
2.8.1 Gastric Cancer Treatment Options 23
2.9 Treatment Guidelines 27
2.10 GlobalData Report Guidance 28
3 Market Characterization 29
3.1 Global 29
3.1.1 Market Size 29
3.1.2 Drivers and Restraints 37
3.1.3 Forecasts 39
3.1.4 Drug Sales 46
3.2 The US 50
3.2.1 Market Size 50
3.2.2 Drivers and Restraints 56
3.2.3 Forecasts 59
3.2.4 Drug Sales 65
3.2.5 Pricing and Reimbursements 68
3.3 The UK 69
3.3.1 Market Size 69
3.3.2 Drivers and Restraints 75
3.3.3 Impact on the Market 77
3.3.4 Forecasts 78
3.3.5 Drug Sales 84
3.3.6 Pricing and Reimbursements 87
3.4 Germany 88
3.4.1 Market Size 88
3.4.2 Drivers and Restraints 94
3.4.3 Impact on the Market 96
3.4.4 Forecasts 97
3.4.5 Drug Sales 103
3.4.6 Pricing and Reimbursements 106
3.5 France 107
3.5.1 Market Size 107
3.5.2 Drivers and Restraints 113
3.5.3 Impact on the Market 114
3.5.4 Forecasts 115
3.5.5 Drug Sales 121
3.5.6 Pricing and Reimbursements 124
3.6 Italy 125
3.6.1 Market Size 125
3.6.2 Drivers and Restraints 131
3.6.3 Impact on the Market 133
3.6.4 Forecasts 134
3.6.5 Drug Sales 140
3.6.6 Pricing and Reimbursements 143
3.7 Spain 144
3.7.1 Market Size 144
3.7.2 Drivers and Restraints 150
3.7.3 Impact on the Market 152
3.7.4 Forecasts 153
3.7.5 Drug Sales 159
3.7.6 Pricing and Reimbursements 162
3.8 Japan 163
3.8.1 Market Size 163
3.8.2 Drivers and Restraints 168
3.8.3 Impact on the Market 169
3.8.4 Forecasts 170
3.8.5 Future Impact 175
3.8.6 Drug Sales 176
3.8.7 Pricing and Reimbursements 179
3.9 Brazil 180
3.9.1 Market Size 180
3.9.2 Drivers and Restraints 185
3.9.3 Impact on the Market 186
3.9.4 Forecasts 187
3.9.5 Future Impact 193
3.10 Russia 194
3.10.1 Market Size 194
3.10.2 Drivers and Restraints 199
3.10.3 Impact on the Market 200
3.10.4 Forecasts 201
3.10.5 Future Impact 206
3.11 India 207
3.11.1 Market Size (2002-2010) 207
3.11.2 Drivers and Restraints 212
3.11.3 Impact on the Market 213
3.11.4 Forecasts (2010-2020) 214
3.11.5 Future Impact 219
3.12 China 220
3.12.1 Market Size (2002-2010) 220
3.12.2 Drivers and Restraints 225
3.12.3 Impact on the Market 226
3.12.4 Impact on the Market 226
3.12.5 Forecasts (2010-2020) 227
3.12.6 Future Impact 232
3.13 Key Takeaway 232
4 Gastric Cancer Market: Competitive Assessment 233
4.1 Strategic Competitor Assessment 233
4.1.1 Overview 233
4.1.2 Benchmarking 234
4.1.3 Current Competitor Assessment 236
4.2 Launch Analysis and Sales Forecasts 238
4.3 Product Profiles of Major Marketed Drugs in the Gastric Cancer Market 239
4.3.1 Herceptin (trastuzumab) 239
4.3.2 Taxotere (docetaxel) 242
4.3.3 Teysuno 243
4.3.4 Xeloda 245
4.4 Key Takeaway 246
5 Gastric Cancer Market: Pipeline Assessment 247
5.1 Overview 247
5.2 Pipeline Analysis by Phase of Development 247
5.3 Pipeline by Mechanism of Action 248
5.4 Strategic Pipeline Assessment 249
5.4.1 Technology Trends Analytic Framework 249
5.5 Gastric Cancer – Promising Drugs Under Clinical Development 251
5.6 Partners in Development 252
5.6.1 Licensing Agreements 252
5.6.2 Research and Development Partnership Agreements 253
5.6.3 Technology and Diagnostic Agreements 255
5.7 Molecule Profile for Promising Drugs Under Clinical Development 256
5.7.1 Tykerb (Lapatinib) 256
5.7.2 Afinitor (Everolimus) 257
5.7.3 IMC-1121B (ramucirumab) 257
5.7.4 Cetuximab plus capecitabine and cisplatin 258
5.7.5 Apatinib (YN968DI) 258
5.8 Key Takeaway 259
6 Clinical Trials Mapping 260
6.1 Clinical Trials 260
6.1.1 Clinical Trials by Status 260
6.1.2 Clinical Trials by Country 261
6.1.3 Clinical Trials by Phase 262
6.1.4 Clinical Trials by Sponsor Type 263
6.1.5 Clinical Trials – Leading Sponsors 264
6.1.6 Clinical Trials – Leading Company Sponsors by Phase 265
6.2 Patient Recruitment 266
7 Opportunity and Unmet Need 267
7.1 Unmet Need 267
7.2 Opportunity for Target Products 269
7.3 Key Takeaway 270
8 Strategic Assessment 271
8.1 Key Events Impacting the Future Market 271
8.2 Market Impact Analysis 272
8.3 Future Market Scenario 272
9 Gastric Cancer Market: Future Players 274
9.1 Introduction 274
9.2 Novartis AG 275
9.2.1 Business Description 275
9.2.2 Financial Overview 276
9.2.3 Gastric Cancer Pipeline 276
9.2.4 SWOT Analysis 277
9.3 GlaxoSmithKline 283
9.3.1 Business Description 283
9.3.2 Financial Overview 284
9.3.3 Gastric Cancer Pipeline 284
9.3.4 SWOT Analysis 285
9.4 Hoffmann-La Roche Ltd. 291
9.4.1 Business Description 291
9.4.2 Financial Performance 293
9.4.3 Gastric Cancer Pipeline 293
9.4.4 SWOT Analysis 294
9.5 Eli Lilly and Company 298
9.5.1 Business Description 298
9.5.2 Financial Overview 300
9.5.3 Gastric Cancer Pipeline 300
9.5.4 SWOT Analysis 301
9.6 Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd. 306
9.6.1 Business Description 306
9.6.2 Gastric Cancer Products 306
9.7 Merck KGaA 307
9.7.1 Business Description 307
9.7.2 Financial Overview 307
9.7.3 Gastric Cancer Pipeline 307
9.7.4 SWOT Analysis 308
10 Gastric Cancer Market: Players in the Gastric Cancer Market 313
10.1 Sanofi-aventis 313
10.1.1 Business Description 313
10.1.2 Financial Overview 315
10.1.3 SWOT Analysis 315
10.1.4 Oncology Focus 320
11 M&A Analysis 321
11.1 Key Highlights 321
11.2 Key Deals' Analysis 323
11.2.1 CrystalGenomics Completes Merger with BexPharm 323
11.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 323
11.2.3 Eli Lilly Acquires ImClone 323
11.2.4 Roche Acquires Additional 9.8% Stake in Chugai Pharmaceuticals 324
12 Expert Opinion 325
12.1 The US 325
12.2 Germany 326
12.3 Italy 326
12.4 Spain 327
12.5 Japan 328
13 Appendix 329
13.1 Market Definitions 329
13.2 Abbreviations 329
13.3 Research Methodology 330
13.3.1 Coverage 330
13.3.2 Secondary Research 331
13.3.3 Forecasting 331
13.3.4 Primary Research 334
13.3.5 Expert Panel validation 334
13.3.6 Contact Us 334
13.3.7 Disclaimer 334
13.3.8 Sources 335
1.1 List of Tables
Table 1: Gastric Cancer Therapeutics Market, Global, Staging of Gastric Cancer, 2010 15
Table 2: Gastric Cancer Therapeutics Market, Global, Risk Factors, 2010 16
Table 3: Gastric Cancer, Global, Results of GI Series X-ray, 2010 19
Table 4: Gastric Cancer, Global, WHO Classification of Gastric Carcinomas, 2010 21
Table 5: Gastric Cancer, Global, Five Year Relative Survival by Stage, 2010 22
Table 6: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011 25
Table 7: Gastric Cancer, Global, Sales Value ($m), 2002-2010 29
Table 8: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2010 31
Table 9: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 33
Table 10: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2002-2010 34
Table 11: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2002-2010 35
Table 12: Gastric Cancer Therapeutics Market, Global, Sales Value ($m), 2010-2020 39
Table 13: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2010-2020 40
Table 14: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2020 41
Table 15: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2010-2020 42
Table 16: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2010-2020 43
Table 17: Gastric Cancer Therapeutics Market, Global, Gastric Cancer Drug Sales ($m), 2002-2010 47
Table 18: Gastric Cancer Therapeutics Market, Global, Gastric Cancer Drug Sales ($m), 2011-2020 48
Table 19: Gastric Cancer Therapeutics Market, the US, Sales Value ($bn), 2002-2010 50
Table 20: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010 51
Table 21: Gastric Cancer Therapeutics Market, the US, Patient Volume (Absolute), 2002-2010 52
Table 22: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2002-2010 54
Table 23: Gastric Cancer Therapeutics Market, the US, Sales Value ($m), 2010-2020 59
Table 24: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2020 60
Table 25: Gastric Cancer Therapeutics Market, the US, Patient Volume (Absolute), 2010-2020 61
Table 26: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2010-2020 62
Table 27: Gastric Cancer Therapeutics Market, the US, Gastric Cancer Drug Sales ($m), 2002-2010 66
Table 28: Gastric Cancer Therapeutics Market, the US, Gastric Cancer Drug Sales ($m), 2011-2020 67
Table 29: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2002-2010 69
Table 30: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2010 71
Table 31: Gastric Cancer Therapeutics Market, the UK, Patient Volume (Absolute), 2002-2010 72
Table 32: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2002-2010 73
Table 33: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2010-2020 78
Table 34: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2010-2020 79
Table 35: Gastric Cancer Therapeutics Market, the UK, Patient Volume (Absolute), 2010-2020 80
Table 36: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2010-2020 81
Table 37: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2002-2010 85
Table 38: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2011-2020 86
Table 39: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2002-2010 88
Table 40: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2010 90
Table 41: Gastric Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2002-2010 91
Table 42: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2002-2010 92
Table 43: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2010-2020 97
Table 44: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2010-2020 98
Table 45: Gastric Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2010-2020 99
Table 46: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2010-2020 100
Table 47: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2002-2010 104
Table 48: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2011-2020 105
Table 49: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2002-2010 107
Table 50: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2010 109
Table 51: Gastric Cancer Therapeutics Market, France, Patient Volume (Absolute), 2002-2010 110
Table 52: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2002-2010 111
Table 53: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2010-2020 115
Table 54: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2010-2020 116
Table 55: Gastric Cancer Therapeutics Market, France, Patient Volume (Absolute), 2010-2020 117
Table 56: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2010-2020 118
Table 57: Gastric Cancer Therapeutics Market, France, Gastric Cancer Drug Sales ($m), 2002-2010 122
Table 58: Gastric Cancer Therapeutics Market, France, Gastric Cancer Drug Sales ($m), 2011-2020 123
Table 59: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2002-2010 125
Table 60: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2010 127
Table 61: Gastric Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2002-2010 128
Table 62: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2002-2010 129
Table 63: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2010-2020 134
Table 64: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2010-2020 135
Table 65: Gastric Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2010-2020 136
Table 66: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2010-2020 137
Table 67: Gastric Cancer Therapeutics Market, Italy, Gastric Cancer Drug Sales ($m), 2002-2010 141
Table 68: Gastric Cancer Therapeutics Market, Italy, Gastric Cancer Drug Sales ($m), 2011-2020 142
Table 69: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2002-2010 144
Table 70: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2010 146
Table 71: Gastric Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2002-2010 147
Table 72: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2002-2010 148
Table 73: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2010-2020 153
Table 74: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2010-2020 154
Table 75: Gastric Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2010-2020 155
Table 76: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2010-2020 156
Table 77: Gastric Cancer Therapeutics Market, Spain, Gastric Cancer Drug Sales ($m), 2002-2010 160
Table 78: Gastric Cancer Therapeutics Market, Spain, Gastric Cancer Drug Sales ($m), 2011-2020 161
Table 79: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2002-2010 163
Table 80: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 164
Table 81: Gastric Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2002-2010 165
Table 82: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2002-2010 166
Table 83: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2010-2020 170
Table 84: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2020 171
Table 85: Gastric Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2010-2020 172
Table 86: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2010-2020 173
Table 87: Gastric Cancer Therapeutics Market, Japan, Gastric Cancer Drug Sales ($m), 2002-2010 177
Table 88: Gastric Cancer Therapeutics Market, Japan, Gastric Cancer Drug Sales ($m), 2011-2020 178
Table 89: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002-2010 180
Table 90: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2010 181
Table 91: Gastric Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2002-2010 182
Table 92: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2002-2010 183
Table 93: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2010-2020 187
Table 94: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2010-2020 188
Table 95: Gastric Cancer, Brazil, Patient Volume (Absolute), 2010-2020 189
Table 96: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2010-2020 191
Table 97: Gastric Cancer, Russia, Sales Value ($m), 2002-2010 194
Table 98: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2002-2010 195
Table 99: Gastric Cancer, Russia, Patient Volume (Absolute), 2002-2010 196
Table 100: Gastric Cancer, Russia, Treatment Usage Patterns, 2002-2010 197
Table 101: Gastric Cancer, Russia, Sales Value ($m), 2010-2020 201
Table 102: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2010-2020 202
Table 103: Gastric Cancer, Russia, Patient Volume (Absolute), 2010-2020 203
Table 104: Gastric Cancer, Russia, Treatment Usage Patterns, 2010-2020 204
Table 105: Gastric Cancer, India, Sales Value ($m), 2002-2010 207
Table 106: Gastric Cancer, India, Annual Cost of Therapy ($), 2002-2010 208
Table 107: Gastric Cancer, India, Patient Volume (Absolute), 2002-2010 209
Table 108: Gastric Cancer, India, Treatment Usage Patterns, 2002-2010 210
Table 109: Gastric Cancer, India, Sales Value ($m), 2010-2020 214
Table 110: Gastric Cancer, India, Annual Cost of Therapy ($), 2010-2020 215
Table 111: Gastric Cancer, India, Patient Volume (Absolute), 2010-2020 216
Table 112: Gastric Cancer, India, Treatment Usage Patterns, 2010-2020 217
Table 113: Gastric Cancer, China, Sales Value ($m), 2002-2010 220
Table 114: Gastric Cancer, China, Annual Cost of Therapy ($), 2002-2010 221
Table 115: Gastric Cancer, China, Patient Volume (Absolute), 2002-2010 222
Table 116: Gastric Cancer, China, Treatment Usage Patterns, 2002-2010 223
Table 117: Gastric Cancer, China, Sales Value ($m), 2010-2020 227
Table 118: Gastric Cancer, China, Annual Cost of Therapy ($), 2010-2020 228
Table 119: Gastric Cancer, China, Patient Volume (Absolute), 2010-2020 229
Table 120: Gastric Cancer, China, Treatment Usage Patterns, 2010-2020 230
Table 121: Gastric Cancer, Global, Clinical Endpoints for Benchmarking, 2010 234
Table 122: Gastric Cancer, Global, Chemotherapy, Safety Profile of Approved Treatment, 2010 235
Table 123: Gastric Cancer, Global, Benchmarking of Major Marketed Products, 2010 239
Table 124: Gastric Cancer – Most Promising Drugs Under Clinical Development, 2010 251
Table 125: Gastric Cancer, Global, Licensing Agreements, 2007-2010 252
Table 126:Gastric Cancer, Global, Research and Development Partnership Agreements, 2009-2010 253
Table 127: Gastric Cancer, Global, Technology and Diagnostic Agreements, 2009-2010 255
Table 128: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011 260
Table 129: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011 261
Table 130: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011 262
Table 131: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011 263
Table 132:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011 264
Table 133:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011 265
Table 134:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011 266
Table 135: Novartis AG – Clinical Pipeline for Gastric Cancer, 2010 276
Table 136: GlaxoSmithKline – Clinical Pipeline for Gastric Cancer, 2011 284
Table 137: Roche – Clinical Pipeline for Gastric Cancer, 2011 293
Table 138: Eli Lilly and Company – Clinical Pipeline for Gastric Cancer, 2011 300
Table 139: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011 306
Table 140: Merck KGaA – Clinical Pipeline for Gastric Cancer, 2011 307
Table 141: Gastric Cancer, Global, M&A Deals, 2010 322
1.2 List of Figures
Figure 1: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011 23
Figure 2: Gastric Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 27
Figure 3: Gastric Cancer, Global, Sales Value ($m), 2002-2010 29
Figure 4: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2010 31
Figure 5: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 33
Figure 6: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2002-2010 34
Figure 7: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2002-2010 35
Figure 8: Gastric Cancer, Global, Market Drivers and Restraints, 2009 37
Figure 9: Gastric Cancer Therapeutics Market, Global, Historical Events Impact on the Market, 2010 38
Figure 10: Gastric Cancer Therapeutics Market, Global, Sales Value ($m), 2010-2020 39
Figure 11: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2010-2020 40
Figure 12: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2020 41
Figure 13: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2010-2020 42
Figure 14: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2010-2020 43
Figure 15: Gastric Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2010-2020 45
Figure 16: Gastric Cancer Therapeutics Market, Global, Gastric Cancer Drug Sales ($m), 2001-2020 46
Figure 17: Gastric Cancer Therapeutics Market, Global, Breakdown of Drug Sales (%), 2010 49
Figure 18: Gastric Cancer Therapeutics Market, the US, Sales Value ($m), 2002-2010 50
Figure 19: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010 51
Figure 20: Gastric Cancer Therapeutics Market, the US, Patient Volume ('000s), 2002-2010 52
Figure 21: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2002-2010 54
Figure 22: Gastric Cancer Therapeutics Market, the US, Market Drivers and Restraints, 2009 56
Figure 23: Gastric Cancer Therapeutics Market, the US, Historical Events Impact on the Market, 2010 58
Figure 24: Gastric Cancer Therapeutics Market, the US, Sales Value ($m), 2010-2020 59
Figure 25: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2020 60
Figure 26: Gastric Cancer Therapeutics Market, the US, Patient Volume ('000s), 2010-2020 61
Figure 27: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2010-2020 62
Figure 28: Gastric Cancer Therapeutics Market, the US, Future Market Drivers and Restraints, 2010-2020 64
Figure 29: Gastric Cancer Therapeutics Market, the US, Gastric Cancer Drug Sales ($m), 2001-2020 65
Figure 30: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2002-2010 69
Figure 31: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2010 71
Figure 32: Gastric Cancer Therapeutics Market, the UK, Patient Volume ('000s), 2002-2010 72
Figure 33: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2002-2010 73
Figure 34: Gastric Cancer Therapeutics Market, the UK, Market Drivers and Restraints, 2009 75
Figure 35: Gastric Cancer Therapeutics Market, the UK, Historical Events Impact on the Market, 2010 77
Figure 36: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2010-2020 78
Figure 37: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2010-2020 79
Figure 38: Gastric Cancer Therapeutics Market, the UK, Patient Volume ('000s), 2010-2020 80
Figure 39: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2010-2020 81
Figure 40: Gastric Cancer Therapeutics Market, the UK, Future Market Drivers and Restraints, 2010-2020 83
Figure 41: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2002-2020 84
Figure 42: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2002-2010 88
Figure 43: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2010 90
Figure 44: Gastric Cancer Therapeutics Market, Germany, Patient Volume ('000s), 2002-2010 91
Figure 45: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2002-2010 92
Figure 46: Gastric Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009 94
Figure 47: Gastric Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010 96
Figure 48: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2010-2020 97
Figure 49: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2010-2020 98
Figure 50: Gastric Cancer Therapeutics Market, Germany, Patient Volume ('000s), 2010-2020 99
Figure 51: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2010-2020 100
Figure 52: Gastric Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2010-2020 102
Figure 53: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2002-2020 103
Figure 54: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2002-2010 107
Figure 55: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2010 109
Figure 56: Gastric Cancer Therapeutics Market, France, Patient Volume ('000s), 2002-2010 110
Figure 57: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2002-2010 111
Figure 58: Gastric Cancer, France, Market Drivers and Restraints, 2009 113
Figure 59: Gastric Cancer, France, Historical Events Impact on the Market, 2010 114
Figure 60: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2010-2020 115
Figure 61: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2010-2020 116
Figure 62: Gastric Cancer Therapeutics Market, France, Patient Volume ('000s), 2010-2020 117
Figure 63: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2010-2020 118
Figure 64: Gastric Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2010-2020 120
Figure 65: Gastric Cancer Therapeutics Market, France, Gastric Cancer Drug Sales ($m), 2002-2020 121
Figure 66: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2002-2010 125
Figure 67: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2010 127
Figure 68: Gastric Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2002-2010 128
Figure 69: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2002-2010 129
Figure 70: Gastric Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009 131
Figure 71: Gastric Cancer Therapeutics Market, Italy, Historical Events Impact on the Market, 2010 133
Figure 72: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2010-2020 134
Figure 73: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2010-2020 135
Figure 74: Gastric Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2010-2020 136
Figure 75: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2010-2020 137
Figure 76: Gastric Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2010-2020 139
Figure 77: Gastric Cancer Therapeutics Market, Italy, Gastric Cancer Drug Sales ($m), 2002-2020 140
Figure 78: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2002-2010 144
Figure 79: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2010 146
Figure 80: Gastric Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2002-2010 147
Figure 81: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2002-2010 148
Figure 82: Gastric Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009 150
Figure 83: Gastric Cancer Therapeutics Market, Spain, Historical Events Impact on the Market, 2010 152
Figure 84: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2010-2020 153
Figure 85: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2010-2020 154
Figure 86: Gastric Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2010-2020 155
Figure 87: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2010-2020 156
Figure 88: Gastric Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2010-2020 158
Figure 89: Gastric Cancer Therapeutics Market, Spain, Gastric Cancer Drug Sales ($m), 2002-2020 159
Figure 90: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2002-2010 163
Figure 91: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 164
Figure 92: Gastric Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2002-2010 165
Figure 93: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2002-2010 166
Figure 94: Gastric Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2009 168
Figure 95: Gastric Cancer Therapeutics Market, Japan, Historical Events Impact on the Market, 2010 169
Figure 96: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2010-2020 170
Figure 97: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2020 171
Figure 98: Gastric Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2010-2020 172
Figure 99: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2010-2020 173
Figure 100: Gastric Cancer Therapeutics Market, Japan, Future Events Expected to Impact the Market, 2010 175
Figure 101: Gastric Cancer Therapeutics Market, Japan, Gastric Cancer Drug Sales ($m), 2001-2020 176
Figure 102: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002-2010 180
Figure 103: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2010 181
Figure 104: Gastric Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2002-2010 182
Figure 105: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2002-2010 183
Figure 106: Gastric Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009 185
Figure 107: Gastric Cancer Therapeutics Market, Brazil, Historical Events Impact on the Market, 2010 186
Figure 108: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2010-2020 187
Figure 109: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2010-2020 188
Figure 110: Gastric Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2010-2020 189
Figure 111: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2010-2020 191
Figure 112: Gastric Cancer Therapeutics Market, Brazil, Future Events Expected to Impact the Market, 2010 193
Figure 113: Gastric Cancer, Russia, Sales Value ($m), 2002-2010 194
Figure 114: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2002-2010 195
Figure 115: Gastric Cancer, Russia, Patient Volume ('000s), 2002-2010 196
Figure 116: Gastric Cancer, Russia, Treatment Usage Patterns, 2002-2010 197
Figure 117: Gastric Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2009 199
Figure 118: Gastric Cancer Therapeutics Market, Russia, Historical Events Impact on the Market, 2010 200
Figure 119: Gastric Cancer, Russia, Sales Value ($m), 2010-2020 201
Figure 120: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2010-2020 202
Figure 121: Gastric Cancer, Russia, Patient Volume ('000s), 2010-2020 203
Figure 122: Gastric Cancer, Russia, Treatment Usage Patterns, 2010-2020 204
Figure 123: Gastric Cancer Therapeutics Market, Russia, Future Events Expected to Impact the Market, 2010 206
Figure 124: Gastric Cancer, India, Sales Value ($m), 2002-2010 207
Figure 125: Gastric Cancer, India, Annual Cost of Therapy ($), 2002-2010 208
Figure 126: Gastric Cancer, India, Patient Volume ('000s), 2002-2010 209
Figure 127: Gastric Cancer, India, Treatment Usage Patterns, 2002-2010 210
Figure 128: Gastric Cancer Therapeutics Market, India, Market Drivers and Restraints, 2009 212
Figure 129: Gastric Cancer Therapeutics Market, India, Historical Events Impact on the Market, 2010 213
Figure 130: Gastric Cancer, India, Sales Value ($m), 2010-2020 214
Figure 131: Gastric Cancer, India, Annual Cost of Therapy ($), 2010-2020 215
Figure 132: Gastric Cancer, India, Patient Volume ('000s), 2010-2020 216
Figure 133: Gastric Cancer, India, Treatment Usage Patterns, 2010-2020 217
Figure 134: Gastric Cancer Therapeutics Market, India, Future Events Expected to Impact the Market, 2010 219
Figure 135: Gastric Cancer, China, Sales Value ($m), 2002-2010 220
Figure 136: Gastric Cancer, China, Annual Cost of Therapy ($), 2002-2010 221
Figure 137: Gastric Cancer, China, Patient Volume ('000s), 2002-2010 222
Figure 138: Gastric Cancer, China, Treatment Usage Patterns, 2002-2010 223
Figure 139: Gastric Cancer Therapeutics Market, China, Market Drivers and Restraints, 2009 225
Figure 140: Gastric Cancer Therapeutics Market, China, Historical Events Impact on the Market, 2010 226
Figure 141: Gastric Cancer, China, Sales Value ($m), 2010-2020 227
Figure 142: Gastric Cancer, China, Annual Cost of Therapy ($), 2010-2020 228
Figure 143: Gastric Cancer, China, Patient Volume ('000s), 2010-2020 229
Figure 144: Gastric Cancer, China, Treatment Usage Patterns, 2010-2020 230
Figure 145:Gastric Cancer Therapeutics Market, China, Future Events Expected to Impact the Market, 2010 232
Figure 146: Gastric Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2011 236
Figure 147: Gastric Cancer Therapeutics Market, Global, Sales Forecast by Therapies, 2001-2020 238
Figure 148: Gastric Cancer, Global, Herceptin, Sales ($m), 2010-2020 241
Figure 149: Gastric Cancer, Globa
To order this report:
: Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article